Cell Cycle Machinery:
The DOI matches its Crossref record, with a small difference in title or year; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Loss of normal growth control is a hallmark of cancer. Thus, understanding the mechanisms of tissue-specific, normal growth regulation and the changes that occur during tumorigenesis may provide insights of both diagnostic and therapeutic importance. Control of cell proliferation in the normal mammary gland is steroid hormone (estrogen and progestin)-dependent, involves complex interactions with other hormones, growth factors and cytokines and ultimately converges on activation of three proto-oncogenes (c-Myc, cyclin D1 and cyclin E1) that are rate limiting for the G1 to S phase transition during normal cell cycle progression. Mammary epithelial cell-specific overexpression of these genes induces mammary carcinoma in mice, while cyclin D1 null mice have arrested mammary gland development and are resistant to carcinoma induced by the neu/erbB2 and ras oncogenes. Furthermore, c-Myc, cyclins D1, E1 and E2 are commonly overexpressed in primary breast cancer where elevated expression is often associated with a more aggressive disease phenotype and an adverse patient outcome. This may be due in part to overexpression of these genes conferring resistance to endocrine therapies since in vitro studies provide compelling evidence that overexpression of c-Myc and to a lesser extent cyclin D1 and cyclin E1, attenuate the growth inhibitory effects of SERMS, antiestrogens and progestins in breast cancer cells. Thus, abnormal regulation of the expression of cell cycle molecules, involved in the steroidal control of cell proliferation in the mammary gland, are likely to be directly involved in the development, progression and therapeutic responsiveness of breast cancer. Furthermore, a more detailed understanding of these pathways may identify new targets for therapeutic intervention particularly in endocrine-unresponsive and endocrine-resistant disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this regard, it is interesting that a key target of RB-mediated repression in senescence is cyclin E1 – a bona fide oncogene whose over-expression occurs in many human tumor types and is often associated with poor prognosis (Butt et al., 2008).”
From Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence (2010) · cites this paper as Butt et al., 2008
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Cited by
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
“MYC is upregulated by estrogen receptor in ERα positive breast cancer cells, through binding to an enhancer located 67 kb upstream of the transcription start site [199–201], and ectopic expression of MYC in cells treated with ERα antagonists can rescue their proliferative defects [202].”
BackgroundXu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R. A., Narita, M., Zhang, M., & Lowe, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.023 · Cited by 388
“In this regard, it is interesting that a key target of RB-mediated repression in senescence is cyclin E1—a bona fide oncogene whose overexpression occurs in many human tumor types and is often associated with poor prognosis (Butt et al., 2008).”
Distinct Properties of Cell-Type-Specific and Shared Transcription Factor Binding Sites
Gertz, J., Savic, D., Varley, K. E., Partridge, E. C., Safi, A., Jain, P., Cooper, G. M., Reddy, T. E., Crawford, G. E., & Myers, R. M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.037 · Cited by 376
“The primary role of estrogens is to direct the development and maintenance of the female reproductive system by promoting cellular proliferation (Butt et al., 2008) and differentiation (Yashwanth et al., 2006); they also influence the musculoskeletal, cardiovascular, immune , and central nervous…”
BackgroundCell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B. M., et al. (2014) · Nature · doi:10.1038/nature13079 · Cited by 361
Metadata
- Authors
- Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer New York
- Published
- 2008
- Volume
- 630
- Pages
- 189-205
- ISSN
- 0065-2598 (ISSN-L)
- OpenAlex
- W94760739
- Cited by
- 59
- References
- 121
- Citations by year
- 2026: 1 · 2025: 2 · 2022: 1 · 2021: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 24.72
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- cell cycle regulation, breast cancer, mammary gland development, c-Myc, cyclin D1, cyclin E1, cyclin E2, steroid hormone signaling, endocrine therapy resistance, tamoxifen resistance, antiestrogens, progestins, proto-oncogenes, G1/S transition, oncogenic Ras
- MeSH terms
- Breast Neoplasms, Cell Cycle, Humans, Models, Biological, Neoplasms, Hormone-Dependent, Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Treatment Outcome, Cyclin-Dependent Kinases, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Cycle Machinery:. https://app.cochat.ai/papers/10.1007/978-0-387-78818-0_12
- The paper
- Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008). Cell Cycle Machinery:. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-0-387-78818-0_12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.